While these immunotherapies have shown striking success, blockade of CTLA-4 and PD-1/PD-L1 are associated with adverse effects that resemble autoimmune disorders, including SLE, RA, thyroiditis, and T1D (59, 101). Here, PDCD1 is linked to type 1 diabetes mellitus.